Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth, as well as investing in service quality, innovation and efficiency.
Vivo Diagnóstico is a large provider of diagnostic imaging services. It owns a network of clinics located in Andalusia, Madrid and Aragon and offers services throughout Spain, providing diagnostic imaging services in mobile units, outsourced diagnostic services for hospitals and teleradiology services.
For over 25 years, the private equity firm, NEXXUS-IBERIA, has partnered with entrepreneurs and management teams to consolidate and accelerate the growth of their businesses.
Oaklins’ team in Spain advised Vivo Diagnóstico on all aspects of the transaction, from the design to the execution, negotiation and closing of the deal.
联系交易团队
相关交易
HD Clinical Ltd. has been acquired by NEXUS AG
NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.
更多信息Reed Veterinary Surgery has been acquired by Kin Vet Community
The acquisition of Reed Veterinary Surgery by Kin Vet Community has been successfully completed. Through this acquisition, the surgery joins a community of veterinary clinics where colleagues share knowledge and best practices to improve the wellbeing of their clients and their animals.
更多信息PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
更多信息